Veranstaltungsprogramm
Eine Übersicht aller Sessions/Sitzungen dieser Tagung.
Bitte wählen Sie einen Ort oder ein Datum aus, um nur die betreffenden Sitzungen anzuzeigen oder eine einzelne Sitzung um die gegebenenfalls vorhandenen Abstracts einsehen zu können.
|
Sitzungsübersicht |
Datum: Donnerstag, 22.02.2024 | ||
11:00 - 12:15 |
Career Workshop: Ort: Wertach Chair: Ingo Hilgendorf, Universitätsklinikum Freiburg Chair: Claudia Göttsch, Universitätsklinikum Aachen Chair: Holger Winkels, Universität zu Köln |
|
12:15 - 13:15 |
Presidents’ Openings and Keynote Ort: Saal Lech Chair: Ulrike Schatz, Universitätsklinikum Dresden Chair: Daniel Sedding, Universitätsklinikum Halle Chair: Oliver Weingärtner, Universitätsklinikum Jena Chair: Nikolaus Marx, Universitätsklinikum Aachen - RWTH Aachen B cell immunity in atherosclerosis Medical University of Vienna, Austria |
|
13:15 - 13:45 |
Break and Exhibition 13:15 - 14:30 Ort: Foyer |
|
13:45 - 14:30 |
Think Tank: Schwere Hypertriglyzeridämie (HTG) - presented by Sobi Ort: Saal Lech Chair: Ulrike Schatz, Universitätsklinikum Dresden Understand Genetics – Nomenklatur und neue Gene bei schwerer HTG Synlab Holding Deutschland GmbH, Mannheim Save the Pancreas – interdisziplinäres Management von HTG-Pankreatitiden Centrum Gastroenterologie Bethanien, Frankfurt a.M. Prevent Pancreatitis – aus der Sicht des Lipidologen Universitätsklinikum Leipzig |
|
14:30 - 16:00 |
Risiko Prädiktion - alles Scores, oder wie? (DE) Ort: Saal Lech Chair: Michael Lehrke, Universitätsklinikum Aachen RWTH Aachen Chair: Ioanna Gouni-Berthold, Universitätsklinikum Köln (AöR) Phänotypologie und Klassifizierungsscores Universitätsklinikum Jena Polygenic risk score - pro (therapieweisend) Synlab Holding Deutschland GmbH, Mannheim Polygenic risk score - against (noch ein weiterer score?) Deutsches Herzzentrum München |
Organ Cross Talk in CVD - session of the AG 41 (ENG) Ort: Wertach Chair: Ingo Hilgendorf, Universitätsklinikum Freiburg Chair: Nikolaus Marx, Universitätsklinikum Aachen - RWTH Aachen CV and Gut Charite Universitätsmedizin Berlin Kidney and CV Universitätsklinikum Aachen, Deutschland Deciphering the role of the liver as a driver of cardiovascular diseases Universitätsklinikum Aachen - RWTH Aachen |
16:00 - 16:15 |
Break and Exhibition 16:00 - 17:00 Ort: Foyer |
|
16:15 - 17:00 |
Lp(a) in der kardiovaskulären Risikostratifizierung - presented by Novartis Ort: Saal Lech Chair: Ioanna Gouni-Berthold, Universitätsklinikum Köln (AöR) Chair: Klaus G. Parhofer, Klinikum der Universität München Lp(a) in der kardiovask. Risikostratifizierung …in der Klinik Universitätsklinikum Dresden Lp(a) in der kardiovask. Risikostratifizierung …in der Niederlassung DIAMEDIKUM Potsdam |
|
17:00 - 18:30 |
Lifestyle Modifikation, aber wie? (DE) Ort: Saal Lech Chair: Frank Edelmann, Charité Berlin Chair: Winfried März, Synlab Holding Deutschland GmbH Intervallfasten und Herzinsuffizienz Universitätsklinikum Halle (Saale) Sport, aber wie(viel)? Universitätsklinikum Leipzig Ess‘ ich‘s oder lass ich‘s lieber sein? Friedrich-Schiller-Universität Jena |
Novel immune pathways in CVD (ENG) Ort: Wertach Chair: Sabine Steffens, LMU München Chair: Florian Kahles, Uniklinikum Aachen Chronic colitis reprograms bone marrow myeloid progenitors thereby accelerating atherosclerosis Institut für Translationale Pharmakologie, Düsseldorf Olfactory receptors in CVD Universität zu Köln Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis Universitätsspital Bern, Schweiz |
18:30 - 20:30 |
Poster Session with "Wine & Cheese" Ort: Foyer Activation of the GLP-1 receptor reduces systemic inflammation in acute and chronic disease models Uniklinik RWTH Aachen, Aachen, Deutschland Changes in macrophage transcriptome in response to cardiac injuries are determined by the type of lesion rather than their ontogenetic nature Universitätsklinikum Freiburg, Freiburg, Deutschland Clonal hematopoiesis of indeterminate potential (CHIP) affects cardiovascular disease severity via pro-inflammatory myeloid cells without increased plaque-side accumulation 1: Department of Cardiology and Angiology I, University of Freiburg, Germany; 2: Department of Internal Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Germany; 3: Department of Cardiology, University Hospital Graz, Austria; 4: Center of Big Data Analysis in Cardiology (CeBAC), Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Germany; 5: Institute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, Germany; 6: Institute of Experimental Cardiovascular Medicine, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Germany Exposure to dietary α-amylase-trypsin inhibitors (ATI) induces vascular inflammation and endothelial dysfunction 1: Laboratory for Molecular Cardiology, University Hospital Mainz, Germany; 2: Institut for Translational Immunology, University Hospital Mainz, Germany; 3: Department of Cardiology, Goethe University Frankfurt am Main, Germany Follow – up in specialized lipid clinics optimizes lipid – lowering therapies in patients with ST – elevation myocardial infarction: a two – year follow – up of “Jena auf Ziel” 1: Klinik für Innere Medizin I, Jena, Deutschland; 2: Klinik für Kardiologie, Angiologie und Intensivmedizin, Charité, Berlin, Deutschland Inhibition of B cell activation by Ibrutinib improves cardiac function in experimental myocardial infarction in mice 1University Heart Centre Freiburg-Bad Krozingen, Medical Centre, University of Freiburg, Germany Intensive lipid – lowering therapy is highly cost effective in patients with ST – elevation myocardial infarction: a two – year follow – up of “Jena auf Ziel” 1: Klinik für Innere Medizin I, Jena, Deutschland; 2: Klinik für Kardiologie, Angiologie und Intensivmedizin, Charité, Berlin, Deutschland; 3: SYNLAB Holding Deutschland GmbH, Augsburg, Deutschland Loss of B cell-ACKR3 reduces atherosclerosis by decreasing plasma cells and pro-inflammatory antibody production 1: Division of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital , Switzerland; 2: DBMR affiliation Department for BioMedical Research, University of Bern, Switzerland; 3: Institute of Cardiovascular Prevention, Department of Medicine, Ludwig-Maximilians-University Munich , Munich, Germany; 4: Division of vascular surgery, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, Switzerland Macrophages require mechano-sensing via Piezo1 to preserve the murine heart Universitätsklinikum Freiburg, Freiburg, Deutschland Modulating cardiac wound healing: profound impact of all-trans retinoic acid (ATRA) on emergency hematopoiesis following myocardial infarction 1: Uniklinik Köln, Köln, Deutschland; 2: Max-Planck-Institut für Immunbiologie und Epigenetik, Freiburg, Deutschland; 3: Uniklinik Freiburg, Freiburg, Deutschland; 4: Center for Systems Biology Massachusetts General Hospital, Boston, USA; 5: Max Grundig Klinik, Bühl, Deutschland Quality Management of Retinal Optical Coherence Tomography-Angiography in the Berlin Long Term Observation of Vascular Events Study (BeLOVE) 1: Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 2: Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; 3: Neuroscience Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 4: Department of Neurology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 5: Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 6: Department of Nephrology and Hypertension, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany; 7: Department of Endocrinology and Metabolism, Charité - Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 8: NutriAct-Competence Cluster Nutrition Research Berlin-Potsdam, Nuthetal, Germany; 9: Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin; 10: German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany; 11: Department of Internal Medicine and Cardiology, Charité–Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Virchow-Klinikum, Augustenburger Platz1, Berlin, 13353, Germany; 12: Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology, Berlin, Germany; 13: Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Center for Stroke Research Berlin, Berlin, Germany; 14: NeuroCure Cluster of Excellence, Charité - Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 15: German Center for Neurodegenerative Diseases (DZNE), Partner Site Berlin, Berlin, Germany; 16: Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; 17: Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 18: Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Molecular Epidemiology Research Group, Berlin, Germany; 19: Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Biobank Technology Platform, Berlin, Germany; 20: Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Institute of Biometry and Clinical Epidemiology; 21: Department of Ophthalmology, Charité - Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 22: Einstein Center Digital Future, Berlin, Germany Senolytical treatment attenuates the susceptibility to ventricular arrhythmias in prediabetes 1: Division of Cardiology, Pulmonology and Vascular Medicine, Duisburg, Deutschland; 2: Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty, Heinrich Heine University, Düsseldorf, Germany; 3: Institute for Pharmacology, Heinrich-Heine-University Düsseldorf, Germany T regulatory cells lose their protective phenotype in patients with coronary artery disease (CAD) Universitäts-Herzzentrum Freiburg-Bad Krozingen, Freiburg, Deutschland The role of ChemR23 in the bidirectional crosstalk between perivascular adipose tissue and arterial vasculature in atherosclerosis 1: Department for BioMedical Research (DBMR),University of Bern, Bern, Schweiz; 2: Department of Vascular Surgery, Inselspital, Bern University Hospital, Bern, Switzerland; 3: Department of Angiology, Inselspital, Bern University Hospital, Bern, Switzerland; 4: Institute for Molecular Cardiovascular Research (IMCAR), RWTH University Hospital Aachen, Aachen, Germany; 5: Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich (LMU), Munich, Germany; 6: DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany Upregulation of endothelial cannabinoid receptor 1 by pro-atherogenic shear stress promotes vascular inflammation 1: LMU Klinikum der Universität München, München, Germany; 2: Institute for Diabetes and Cancer, Helmholtz Zentrum Munich, Neuherberg, Germany; 3: DZHK (German Center for Cardiovasular Research), Partner Site Munich Heart Alliance, Munich Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients - Results from the efficacy phase of the APH-19 study 1: Amryt Research Limited, Amryt Pharma, Dublin, Ireland; 2: Unitat De Medicina Vascular I Metabolisme, Hospital Universitari Sant Joan de Reus, Reus, Spain; 3: Department Of Medicine, University of Padua, Padua, Italy; 4: Centre For Pediatric And Adolescent Medicine, University of Heidelberg, Heidelberg, Germany; 5: Department Of Paediatrics, University Hospital Cologne, Cologne, Germany; 6: Department Of Paediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 7: Sackler Faculty Of Medicine, Tel-Aviv University, Tel Aviv, Israel; 8: Rare Diseases And Medical Genetics Unit, Bambino Gesù Children's Hospital, Rome, Italy; 9: Heart Center Department, King Faisal Specialist Hospital And Research Center, Alfaisal University College of Medicine, Riyadh, Saudi Arabia; 10: Department Of Pediatrics, King Abdullah Specialist Children Hospital, Riyadh, Saudi Arabia; 11: Department Of Internal Medicine, A Coruña University Hospital, A Coruña, Spain; 12: Cardiology B Department, Fattouma Bourguiba University Hospital, Monastir, Tunisia; 13: Department Of Endocrinology And Nutrition, Clinic University Hospital of Valencia, Valencia, Spain; 14: Consultancy, Solara Consulting Corp., North Vancouver, Canada Deletion of adipocyte NOS3 potentiates high-fat diet-induced hypertension and vascular remodeling via chemerin Universitätsmedizin Mainz, Mainz, Deutschland Effect of microplastics on experimental atherosclerosis, microbiome Philipps-Universität Marburg, Marburg, Deutschland CD40-TRAF6 inhibition improves functional and structural outcome in acute myocardial infarction by inhibiting pro-fibrotic macrophages 1: Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty and University Hospital, Heinrich-Heine University, Düsseldorf, Germany; 2: BMFZ, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; 3: Cardiovascular Research Institute Düsseldorf (CARID), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; 4: Department of Cardiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; 5: Cardiovascular Medicine, Experimental CardioVascular Immunology Laboratory, Mayo Clinic, Rochester, MN, USA; 6: The authors contributed equally to this study Novel fluorescence-based methods to determine infarct and scar size in murine models of myocardial infarction Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty and University Hospital, Heinrich-Heine University, Düsseldorf, Germany Lipoprotein(a) and subclinical carotid atherosclerosis: Results from the population-based Hamburg City Health Study (HCHS) 1: University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2: German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Luebeck, Ham-burg, Germany; 3: Center for Population Health Innovation (POINT), University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 4: University Center of Cardiovascular Science at University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 5: Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany |
Datum: Freitag, 23.02.2024 | |
8:00 - 10:00 |
Young Investigator Session Ort: Saal Lech Chair: Karsten Grote, Philipps-Universität Marburg Chair: Andreas Zirlik, Medizinische Universität Graz Adjustment of the SMART risk score by bioactive adrenomedullin enables a more accurate prediction of mortality in patients with ASCVD 1: Med. Klinik I - Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen, Aachen; 2: Sphingotec GmbH, Hennigsdorf; 3: Med. Klinik V - Klinik für Pneumologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen, Aachen; 4: RWTH cBMB am Institut für Pathologie, Uniklinik RWTH Aachen, Aachen Association between BMI and cause-specific long-term mortality in acute myocardial infarction patients. 1: Epidemiology, Medical Faculty, University of Augsburg, Augsburg, Germany; 2: University Hospital Augsburg, Department of Cardiology, Respiratory Medicine and Intensive Care, Augsburg, Germany ChemR23 expression protects against smooth muscle cell phenotype switching in atherosclerosis 1: Division of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern, Switzerland; 2: Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland; 3: 3Graduate School for Cellular and Biomedical Sciences, University of Bern, Switzerland; 4: Department of Vascular Surgery, University Hospital Bern, 3010 Bern, Switzerland; 5: Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich (LMU), 80336 Munich, Germany; 6: Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany; 7: Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; 8: DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, 80336 Munich, Germany Comprehensive and parallel analysis of different cardiovascular diseases using CITE-sequencing 1: Division for Cardiology, Pulmonology and Vascular Medicine, Medical Faculty and University Hospital, Heinrich-Heine University, Düsseldorf, Germany; 2: Genomics and Transcriptomics Laboratory, Biologisch-Medizinisches-Forschungszentrum (BMFZ), Heinrich Heine University Düsseldorf, Germany; 3: Department of Cardiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany GLP-1 provides significant added value on top of the SMART risk score for prediction of cardiovascular mortality in patients with coronary artery disease: the LURIC study 1: Department of Internal Medicine I - Cardiology, Angiology and Internal Intensive Care Medicine, University Hospital RWTH Aachen, Aachen, Germany; 2: Vth Department of Medicine (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 3: Cardiovascular Department, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Università della Svizzera Italiana, Lugano, Switzerland; 4: Pneumology and Intensive Care Medicine Department, University Hospital RWTH Aachen, Aachen, Germany; 5: Department of Medicine III - Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Aachen, Germany; 6: SYNLAB Holding Deutschland GmbH, SYNLAB Academy, Mannheim, Germany Gut immune cells are upregulated in heart failure and aggravate left ventricular dysfunction in mice 1: Uniklinik RWTH Aachen, Aachen, Deutschland; 2: Uniklinik Köln, Köln, Deutschland Loss of B cell-ACKR3 reduces atherosclerosis by decreasing plasma cells and pro-inflammatory antibody production 1: Division of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital , Switzerland; 2: DBMR affiliation Department for BioMedical Research, University of Bern, Switzerland; 3: Institute of Cardiovascular Prevention, Department of Medicine, Ludwig-Maximilians-University Munich , Munich, Germany; 4: Division of vascular surgery, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, Switzerland Macrophage expressed CD36 promotes plaque vulnerability in atherosclerosis 1: University Heart Center Freiburg - Bad Krozingen, Freiburg, Germany; 2: Institute of Experimental Biomedicine, University Hospital Wuerzburg, Wuerzburg, Germany; 3: Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht, Netherlands Reversibility of Cardiovascular Impacts in Celiac Disease: Insights from a Gluten-Free Diet Intervention Study 1: Center for Cardiolog, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; 2: Institute of Translational Immunology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; 3: Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany; 4: German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz/Frankfurt a. M., Germany; 5: Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland; 6: Farncombe Digestive Disease Center, McMaster University, Hamilton, Canada; 7: Division of Cardiology, Goethe University Frankfurt, University Hospital, Department of Medicine III, Germany; 8: Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Senolytics reduce inflammation and neutrophil migration in pre-diabetic murine hearts 1: Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty and University Hospital, Heinrich-Heine University, Düsseldorf, Germany; 2: BMFZ, Heinrich-Heine Universität, Düsseldorf, Deutschland The role of ChemR23 in the bidirectional crosstalk between perivascular adipose tissue and arterial vasculature in atherosclerosis 1: Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland; 2: Department of Vascular Surgery, Inselspital, Bern University Hospital, Bern, Switzerland; 3: Department of Angiology, Inselspital, Bern University Hospital, Bern, Switzerland; 4: Institute for Molecular Cardiovascular Research (IMCAR), RWTH University Hospital Aachen, Aachen, Germany; 5: Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich (LMU), Munich, Germany; 6: DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany |
10:00 - 10:15 |
Break and Exhibition 10:00 - 11:00 Ort: Foyer |
10:15 - 11:00 |
Der Blick über den Tellerrand: Individualisierte Therapieansätze bei kardiovaskulären Hochrisikopatienten - presented by Daiichi Sankyo Ort: Saal Lech Chair: Oliver Weingärtner, Universitätsklinikum Jena Erkenntnisse zur Bempedoinsäure: Ergebnisse aus den Subgruppenanalysen Universitätsklinikum Mannheim hsCRP oder LDL-C Senkung - Neue Targets oder Altbewährtes? Universitätsklinikum Freiburg |
11:00 - 12:30 |
Neue Konzepte im Lipid- und Glukosestoffwechsel (DE) Ort: Saal Lech Chair: Dirk Müller-Wieland, Universitätsklinikum Aachen RWTH Aachen Chair: Ulrike Schatz, Universitätsklinikum Dresden HDL - zuviel des Guten? Universität Zürich, Schweiz Triglyzeridreiche Lipoproteine (TRL): Klinische Bedeutung und therapeutische Konsequenzen Endokrinologikum Hamburg Die Heterogenität des Stoffwechsels vom Prädiabetes bis zum Diabetes Deutsches Diabetes-Zentrum, Düsseldorf |
12:30 - 12:45 |
Break and Exhibition 12:30 - 13:30 Ort: Foyer |
12:45 - 13:30 |
Homozygote familiäre Hypercholesterinämie – Therapieoptionen für Kinder und Erwachsene - presented by Ultragenyx Ort: Saal Lech Chair: Gerald Klose, Praxis Dr. Beckenbauer & Dr. Maierhof EAS-Konsensus: Was ist neu? Was ist wichtig? Klinikum der Universität München Neue Studien & Fallbesprechung LMU, Medizinische Klinik IV, München |
13:30 - 15:00 |
Cardiovascular aging (ENG) Ort: Saal Lech Chair: Norbert Gerdes, Universitätsklinikum Düsseldorf Chair: Michael Torzewski, Robert-Bosch-Krankenhaus GmbH CHIP - Impact on Cardiovascular Disease Deutsches Herzzentrum München Age-associated immunity in atherosclerosis Leiden University, Niederlande Organ crosstalk in cardiovascular disease - Lecture Schönheimer Medal DGAF Universitätsklinikum Aachen |
15:00 - 15:15 |
Break and Exhibition 15:00 - 16:00 Ort: Foyer |
15:15 - 16:00 |
Lower, Earlier, Longer - Paradigmenwechsel in der Lipidtherapie - presented by Sanofi Aventis Ort: Saal Lech Chair: Daniel Sedding, Universitätsklinikum Halle Bewusstsein schaffen für eine intensive, frühe und langanhaltende Lipidtherapie. Universitätsklinikum Halle (Saale) Lower, Earlier, Longer - Von der Plaque Modulation, über Stabilisierung bis hin zur Regression. Deutsches Herzzentrum München |
16:00 - 17:00 |
DGAF Members assembly Ort: Saal Lech |
17:00 - 18:30 |
OMICS technologies and data science in CVD (ENG) Ort: Saal Lech Chair: Dennis Wolf, Uniklinik Freiburg Chair: Alma Zernecke-Madsen, Universitätsklinikum Würzburg Proteomics Strategies to Identify New Diagnostic and Therapeutic Targets in CVD Imperial College, London, UK Spatial atlas of Human Atherosclerosis for target discovery Universitätsklinikum Aachen System biology approaches for CVD Helmholtz München |
19:00 - 22:30 |
Conference Dinner Ort: Riegele Brauhaus |
Datum: Samstag, 24.02.2024 | ||
9:00 - 10:30 |
Guidelines (DE) Ort: Saal Lech Chair: Wolfgang Koenig, Deutsches Herzzentrum München Chair: Martin Merkel, Endokrinologikum Hamburg Diabetes Universitätsklinikum Aachen Herzinsuffizienz Universitätsklinikum Halle (Saale) Hypertonie Universitätsklinikum Düsseldorf |
Mechanism of non-traditional risk factors (ENG) Ort: Wertach Chair: Claudia Göttsch, Universitätsklinikum Aachen Chair: Stefan Lorkowski, Friedrich-Schiller-Universität Jena Air pollution and cardiovascular disease Universitätsklinikum Freiburg Climate change and CVD Helmholtz Zentrum München Psychosocial stress in CVD Deutsches Herzzentrum München |
10:30 - 11:00 |
Break and Exhibition Ort: Foyer |
|
11:00 - 12:00 |
Moderne Bildgebung in kardiovaskulärer Medizin (DE) Ort: Saal Lech Chair: Daniel Sedding, Universitätsklinikum Halle Chair: Oliver Weingärtner, Universitätsklinikum Jena Intravaskuläre Bildgebung/precision PCI Universitätsklinikum Frankfurt Mikrovaskuläre Gefässanalyse TU Ilmenau |
Atherothrombosis (ENG) Ort: Wertach Chair: Yvonne Döring, Universitätsspital Bern Chair: Timoteo Marchini, Universitätsklinikum Freiburg Neutrophil Extracellular Traps in ACS Universitätsklinikum Freiburg Platelets secreted mediators - mechanisms and clinical relevance Universitätsmedizin Mannheim |
12:10 - 12:45 |
Awards and Closing remarks Ort: Saal Lech Chair: Daniel Sedding, Universitätsklinikum Halle Chair: Oliver Weingärtner, Universitätsklinikum Jena Chair: Ulrike Schatz, Universitätsklinikum Dresden |
Impressum · Kontaktadresse: Datenschutzerklärung · Veranstaltung: VMAC 2024 |
Conference Software: ConfTool Pro 2.6.149 © 2001–2024 by Dr. H. Weinreich, Hamburg, Germany |